Artesunate/amodiaquine
| Combination of | |
|---|---|
Antimalarial | |
| Clinical data | |
| Trade names | Camoquin, others[1] |
| Other names | ASAQ |
| ATC code | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Artesunate/amodiaquine, sold under the trade name Camoquin among others, is a medication used for the treatment of malaria.[3][4] It is a fixed-dose combination of artesunate and amodiaquine.[3] Specifically it recommended for acute uncomplicated Plasmodium falciparum malaria.[5] It is taken by mouth.[4]
Common side effects include loss of appetite, nausea, abdominal pain, sleepiness, trouble sleeping, and cough.[6] Safety in pregnancy is not clear; however, the medication may be used if others are not possible.[6] It is believed to be safe for use during breastfeeding.[6] Artesunate and amodiaquine are both antimalarial medication; however, work by different mechanisms.[6]
Artesunate/amodiaquine was commercially launched in 2007.
Medical uses
Early clinical trials showed that a once-a-day dosage was effective.[9] It was subsequently clinically shown to be equally effective as artemether/lumefantrine,[10] although it is likely to be more effective in the field due to its simpler once-a-day dosage compared to artemether/lumefantrine twice-per-day dosage.
Society and culture
Artesunate/amodiaquine was commercially launched in 2007 as an affordable treatment for malaria, devised by
References
- ^ ISBN 9781118819517. Archivedfrom the original on 2016-12-20.
- ^ https://go.drugbank.com/drugs/DB09274
- ^ hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ PMID 17352806.
- ISBN 9789241547659.
- ^ a b c d "Artesunate Amodiaquine Winthrop" (PDF). WIPO. August 2010. Archived (PDF) from the original on 24 October 2016. Retrieved 12 December 2016.
- ^ a b c "New, Once-a-Day Fixed-Dose Combination Against Malaria Now Available – DNDi". www.dndi.org. 1 March 2007. Archived from the original on 20 December 2016. Retrieved 12 December 2016.
- ISBN 9780323322850. Archivedfrom the original on 2016-12-20.
- PMID 19505304.
- PMID 21838909.
- ^ "DNDi passes the ball to MMV | Medicines for Malaria Venture". www.mmv.org. 22 May 2015. Retrieved 2020-02-13.
External links
- Patient Leaflet
- Monograph (2010) Archived 2021-08-27 at the Wayback Machine
